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Community acquired respiratory virus infections (CARV) among patients with lung transplantation (LT) are reported to worsen outcomes due to immunomodulatory effects. The current study evaluated the incidence, patient characteristics, management approaches and three year outcomes after CARV during the first year after LT.

**PURPOSE:** This was a retrospective study that included patients transplanted from 2012-14 (n=193, mean age 56±14 years, M:F113: 80). We reviewed baseline characteristics, pre and post LT course including CARV during the first year and management strategies. Diagnosis of CARV was established by respiratory viral PCR from nasal swab. Chronic lung allograft dysfunction (CLAD, obstructive or restrictive) was diagnosed by prospective assessment of each patient chart. Primary outcome variable was CLAD free survival at 3 years.

**METHODS:** Nearly one-fifth of patients developed CARV (n=37) and incidence peaked between 3-9 months post LT (25/37, 67.6%). Viruses isolated included Rhinovirus (n=10), Coronavirus (n=8), Respiratory Syncytial Virus (n=6) and Influenza (n=6). Presenting symptoms included lower respiratory tract symptoms (75.7%) and \>10% decline in spirometry (43.2%). Majority required hospitalization (51.3%) with median duration of six days (range 2-39 days). A third of the patients received inhaled ribavirin and corticosteroid pulse (n=13) along with intravenous immunoglobulin or palivizumab (n=14). The remaining patients were treated with oral prednisone burst and antibiotics. Apart from a protective effect of history of hyperlipidemia in the pre-transplant period (21.6% vs 40.4%; OR, 95% CI: 0.41, 0.18-0.95, p=0.033), none of the variables such as immunosuppressive regimen, immunoglobulin levels, lymphocyte counts and the Cylex® assay were associated with CARV. CARV was associated with a significant but transient loss in vital capacity during the first year (0.28±0.42L vs 0.1±0.32L, p=0.026). CLAD free survival at 3 years among patients with or without CARV during the first year was similar (54.1% vs 43.2%, p=0.235; see Figure).

**RESULTS:** Development of CARV is common after LT with the highest risk during 3-9monthsafter LT. Apart from the protective effect of hyperlipidemia (possibly due to statin use), none of the demographic or clinical variables predict CARV development. Despite a significant decline in lung functions during the first year, CARV did not worsen the 3 years CLAD free survival in this cohort.

**CONCLUSIONS:** Aggressive management may attenuate the increased risk of CLAD or mortality after CARV infections.

**CLINICAL IMPLICATIONS:**

**DISCLOSURES:** No relevant relationships by Amit Banga, source=Web Response No relevant relationships by Srinivas Bollineni, source=Web Response No relevant relationships by Ricardo La Hoz, source=Web Response No relevant relationships by Luke Mahan, source=Web Response No relevant relationships by Manish Mohanka, source=Web Response no disclosure on file for Jessica Mullins; no disclosure on file for Fernando Torres;
